



Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	wo-9605863-\$.did.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:37
L2	4	pct and "99" and "30393"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:38
L7	26028	hydrazide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L8	149	hydrazide and dox	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L9	4942	hydrazide and top	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L10	56	(hydrazide and dox) and (hydrazide and top)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L11	876	succinyl and prodrug	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L12	648	(succinyl and prodrug) and peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L13	785	succinyl same peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L14	11	(succinyl same peptide) same prodrug	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L15	2	WO-9605863-\$.did.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L16	0	WO-9605863-\$.did. and succinyl	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41

L17	2	"5962216".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L18	1	"5962216".pn. and succinyl	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L19	0	"09879442".did.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L20	0	"09879442".an.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L21	26	((("4277466") or ("4296106") or ("4376765") or ("4388305") or ("4639456") or ("4671958") or ("4703107") or ("4719312") or ("4870162") or ("5024835") or ("5220001") or ("5599686") or ("5962216"))).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/06/23 14:41
L22	13	((("4277466") or ("4296106") or ("4376765") or ("4388305") or ("4639456") or ("4671958") or ("4703107") or ("4719312") or ("4870162") or ("5024835") or ("5220001") or ("5599686") or ("5962216"))).PN.	USPAT; USOCR	OR	OFF	2005/06/23 14:41
L23	2	("6372712").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/06/23 14:41
L24	1	((("6372712").PN.) and hydrazide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/06/23 14:41
L25	0	wo-0033888-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/06/23 14:42
L26	54	"0033888"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/06/23 14:43

L27	12	"00/33888"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/06/23 15:01
L28	6862	514/2.ccls.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/06/23 15:01
L29	3621	530/300,326330.ccls.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/06/23 15:03
L30	8811	530/300,326-330.ccls.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/06/23 15:03
L31	2	I30 and (therapeutic and \$peptide and stabiliz\$ and linker).clm.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/06/23 15:04
S1	24278	hydrazide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 13:37
S2	123	hydrazide and dox	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/23 12:11
S3	4424	hydrazide and top	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/23 12:12
S4	48	(hydrazide and dox) and (hydrazide and top)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/23 12:12
S5	733	succinyl and prodrug	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 13:51
S6	552	(succinyl and prodrug) and peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 13:51

S7	694	succinyl same peptide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 13:52
S8	8	(succinyl same peptide) same prodrug	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 13:52
S9	2	WO-9605863-\$.did.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 13:52
S10	0	WO-9605863-\$.did. and succinyl	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 13:53
S11	2	"5962216".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 14:16
S12	1	"5962216".pn. and succinyl	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 15:01
S13	0	"09879442".did.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 15:01
S14	0	"09879442".an.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 15:18
S15	26	((("4277466") or ("4296106") or ("4376765") or ("4388305") or ("4639456") or ("4671958") or ("4703107") or ("4719312") or ("4870162") or ("5024835") or ("5220001") or ("5599686") or ("5962216"))).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2004/10/25 15:20
S16	13	((("4277466") or ("4296106") or ("4376765") or ("4388305") or ("4639456") or ("4671958") or ("4703107") or ("4719312") or ("4870162") or ("5024835") or ("5220001") or ("5599686") or ("5962216"))).PN.	USPAT; USOCR	OR	OFF	2004/10/25 15:20
S17	2	("6372712").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2004/10/25 17:30

S18	1	("6372712").PN.) and hydrazide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/10/25 17:30
-----	---	--------------------------------	---	----	----	------------------



[All Databases](#)
[PubMed](#)
[Nucleotide](#)
[Protein](#)
[Genome](#)
[Structure](#)
[OMIM](#)
[PMC](#)
[Journals](#)
[Books](#)

Search **PubMed** for **succinyl prodrug** [Preview](#) [Go](#) [Clear](#)

[Limits](#)
[Preview/Index](#)
[History](#)
[Clipboard](#)
[Details](#)

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Search

Most Recent Queries

#2 Search **succinyl prodrug**

Time Result

17:01:25 22

[Clear History](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jun 23 2005 09:55:42

FILE 'HOME' ENTERED AT 14:21:22 ON 23 JUN 2005

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 14:21:32 ON 23 JUN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JUN 2005 HIGHEST RN 852803-45-3

DICTIONARY FILE UPDATES: 22 JUN 2005 HIGHEST RN 852803-45-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s

['bal''nal''aib'alm][lyfvwmpag'nle''nva''phg'] [lfiagysft'nal''hse''bal'] [alygstf'hse''nle''aib']/sqsp

L1 3730968 ['BAL''NAL''AIB'ALM][LYFVWMPAG'NLE''NVA''PHG'] [LFIAGYSFT'NAL''HSE''BAL'] [ALYGSTF'HSE''NLE''AIB']/SQSP

=> l1 and sql=<20

3717644 SQL=<20

L2 98737 L1 AND SQL=<20

=> l2 and sql>=4

57323380 SQL>=4

L3 98737 L2 AND SQL>=4

=> s l3 and

['bal''nal''aib'] [lyfvwmpag'nle''nva''phg'] [lfiagysft'nal''hse''bal'] [alygstf'hse''nle''aib']/sqsp

1893 ['BAL''NAL''AIB'] [LYFVWMPAG'NLE''NVA''PHG'] [LFIAGYSFT'NAL''HSE''

BAL'] [ALYGSTF'HSE''NLE''AIB']/SQSP
L4 1893 L3 AND ['BAL''NAL''AIB'] [LYFVWMPAG'NLE''NVA''PHG'] [LFIAGYSFT'NAL
'HSE''BAL'] [ALYGSTF'HSE''NLE''AIB']/SQSP

=> fil hcaplus; l4

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	66.78	66.99

FILE 'HCAPLUS' ENTERED AT 14:25:19 ON 23 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Jun 2005 VOL 142 ISS 26
FILE LAST UPDATED: 22 Jun 2005 (20050622/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L5 879 L4

=> l5 and therapeutic

182509 THERAPEUTIC
19129 THERAPEUTICS
196869 THERAPEUTIC
(THERAPEUTIC OR THERAPEUTICS)

L6 31 L5 AND THERAPEUTIC

=> l6 and conjugate

60984 CONJUGATE
53927 CONJUGATES
94098 CONJUGATE
(CONJUGATE OR CONJUGATES)

L7 11 L6 AND CONJUGATE

=> d l7 1-11 ibib abs hitstr

L7 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:159927 HCAPLUS Full-text
DOCUMENT NUMBER: 142:254652
TITLE: Potentiation of the activation of high-molecular-weight prodrugs for therapeutic or diagnostic use
INVENTOR(S): Trouet, Andre; Dubois, Vincent
PATENT ASSIGNEE(S): Diatos, Fr.

SOURCE: Fr. Demande, 64 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2858936	A1	20050225	FR 2003-10114	20030822
WO 2005021043	A2	20050310	WO 2004-FR2162	20040819

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: FR 2003-10114 A 20030822

AB The invention discloses a modified form of a prodrug. The prodrugs of the invention include a bulky group, a spacer, a structure cleavable in the circulation, and a therapeutic agent or a marker. The spacer allows or facilitates the cleavage of the cleavable structure. Preparation of PEG-peptide-doxorubicin conjugates is included.


IT 274912-87-7


RL: PAC (Pharmacological activity); BIOL (Biological study)
 (potentiation of activation of high-mol.-weight prodrugs for
 therapeutic or diagnostic use)

RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)- β -alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






IT 177953-71-8DP, conjugates with PEG and doxorubicin
 845815-56-7DP, conjugates with PEG and doxorubicin
 845815-58-9DP, conjugates with PEG and doxorubicin
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(potentiation of activation of high-mol.-weight prodrugs for
 therapeutic or diagnostic use)

RN 177953-71-8 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 845815-56-7 HCAPLUS

CN L-Leucine, D-seryl-D-seryl-D-seryl-D-seryl- β -alanyl-L-leucyl-L-alanyl-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 845815-58-9 HCAPLUS

CN L-Leucine, D-seryl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 274912-97-9 845815-54-5 845815-55-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(potentiation of activation of high-mol.-weight prodrugs for
therapeutic or diagnostic use)

RN 274912-97-9 HCAPLUS

CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845815-54-5 HCAPLUS

CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-D-seryl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 845815-55-6 HCAPLUS

CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-D-seryl-D-seryl-D-seryl-D-seryl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:772189 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:8611
 TITLE: Physical polymer matrixes based on affinity interactions between peptides and polysaccharides
 AUTHOR(S): Seal, Brandon L.; Panitch, Alyssa
 CORPORATE SOURCE: The Harrington Department of Bioengineering, Arizona State University, Tempe, AZ, 85287-9709, USA
 SOURCE: Biomacromolecules (2003), 4(6), 1572-1582
 CODEN: BOMAF6; ISSN: 1525-7797
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal

LANGUAGE: English

AB A rapidly forming polymer matrix with affinity-based controlled release properties was developed based upon interactions between heparin-binding peptides and heparin. Dynamic mech. testing of 10% (w/v) compns. consisting of a 3:1 molar ratio of poly(ethylene glycol)-co-peptide (.apprx.18 000 g/mol) to heparin (.apprx.18 000 g/mol) revealed a viscoelastic profile similar to that of concentrated, large mol. weight polymer solns. and melts. In addition, the biopolymer mixts. recovered quickly following thermal denaturation and mech. insult. These gel-like materials were able to sequester exogenous heparin-binding peptides and could release these peptides over several days at rates dependent on relative heparin affinity. The initial release rates ranged from 3.3% per h for a peptide with low heparin affinity to 0.025% per h for a peptide with strong heparin affinity. By altering the affinity of peptides to heparin, a series of peptides can be developed to yield a range of release profiles useful for controlled in vivo delivery of therapeutics.


IT 627503-59-7DP, reaction product with PEG vinyl sulfone

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(phys. polymer matrixes based on affinity interactions between peptides and polysaccharides)

RN 627503-59-7 HCAPLUS

CN L-Alanine, N-[[[3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5(or 6)-yl]amino]thioxomethyl]-β-alanyl-L-alanyl-L-alanyl-L-phenylalanyl-L-alanyl-L-lysyl-L-leucyl-L-alanyl-L-alanyl-L-arginyl-L-leucyl-L-tyrosyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)




PAGE 1-A



$$\begin{array}{c}
 \text{Me}-\text{CH}-\text{C}-\text{NH} \\
 | \quad || \\
 \text{H}_2\text{N}-(\text{CH}_2)_4-\text{CH}-\text{C}-\text{NH} \\
 | \quad || \quad | \\
 \text{i-Bu}-\text{CH}-\text{C}-\text{NH} \\
 | \quad || \\
 \text{Me}-\text{CH}-\text{C}-\text{NH} \\
 | \quad || \\
 \text{H}_2\text{N}-\text{C}-\text{NH}
 \end{array}$$
$$\begin{array}{c}
 \text{---NH} \quad \text{O} \\
 | \quad \parallel \\
 \text{---CH---C---NH} \\
 | \quad \parallel \quad \text{O} \\
 \text{Me---CH---C---NH} \\
 | \quad \parallel \quad \text{O} \\
 \text{---NH---(CH}_2\text{)}_3\text{---CH---C---NH} \\
 | \quad \parallel \quad \text{O} \\
 \text{i-Bu---CH---C---NH} \\
 | \quad \parallel \quad \text{O} \\
 \text{CH}_2\text{---CH---C---NH---CH---(CH}_2\text{)}_3\text{---NH---C---NH}_2 \\
 | \quad \parallel \quad \text{O} \quad \parallel \quad \text{O} \quad \text{Me} \\
 \text{C---NH---CH---(CH}_2\text{)}_4\text{---NH}_2 \quad \text{C---NH---CH---CO}_2\text{H} \\
 | \quad \parallel \quad \text{O} \quad \parallel \quad \text{O} \\
 \text{C---NH---CH---(CH}_2\text{)}_3\text{---NH---C---NH}_2 \\
 | \quad \parallel \quad \text{O} \quad \parallel \quad \text{O} \\
 \text{C---NH---CH---(CH}_2\text{)}_4\text{---NH}_2 \quad \text{C---NH---CH---CO}_2\text{H}
 \end{array}$$

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(phys. polymer matrixes based on affinity interactions between peptides
and polysaccharides)


CN L-Alanine, N-[[[3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9']-[9H]xanthen]-5(or 6)-yl]amino]thioxomethyl]-β-alanyl-L-alanyl-L-alanyl-L-phenylalanyl-L-alanyl-L-lysyl-L-leucyl-L-alanyl-L-alanyl-L-arginyl-L-leucyl-L-tyrosyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:927432 HCAPLUS Full-text
 DOCUMENT NUMBER: 138:4470
 TITLE: Preparation of duocarmycin analogs as potent cytotoxins
 INVENTOR(S): Ng, Howard P.; McGee, Danny P. C.; Wu, Guoxian; Li, Zhihong; Gangwar, Sanjeev; Saunders, Oliver L.; Martichonok, Valeri; Astafieva, Irina; Moore, Jimmie; Yarranton, Geoffrey Thomas; King, David J.; Boyd, Sharon; Lobl, Thomas J.
 PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
 SOURCE: PCT Int. Appl., 118 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096910	A1	20021205	WO 2002-US17210	20020531
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448319	AA	20021205	CA 2002-2448319	20020531
US 2003050331	A1	20030313	US 2002-160972	20020531
US 2003064984	A1	20030403	US 2002-161234	20020531
US 2003073852	A1	20030417	US 2002-161233	20020531
NZ 529788	A	20031219	NZ 2002-529788	20020531
EP 1434778	A1	20040707	EP 2002-731994	20020531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500273	T2	20050106	JP 2003-500089	20020531
ZA 2003000735	A	20040623	ZA 2003-735	20030128
PRIORITY APPLN. INFO.:			US 2001-295196P	P 20010531
			US 2001-295259P	P 20010531
			US 2001-295342P	P 20010531
			US 2001-304908P	P 20010711
			WO 2002-US17210	W 20020531
OTHER SOURCE(S):		MARPAT 138:4470		
GI				



AB Duocarmycin analogs I [X, Z = O, S, or imino; R1 = H, (un)substituted alkyl, carboxylic acid, ester, or amide; R2 = H, (un)substituted alkyl; R3 = :O, OH or derivative; R4, R5 = H, (un)substituted alkyl, (hetero)aryl, heterocycloalkyl, halo, NO₂, NR15R16, NCOR15, O₂CNR15R16, OCO₂R15, COR5, OR15, where R15 and R16 = H, (un)substituted (hetero)alkyl, (hetero)aryl, heterocycloalkyl, or peptidyl or NR15R16 = (un)substituted 4-6 membered heterocycloalkyl; R6 = a single bond; R7 = CH₂-X, where X is a leaving group; or R6 and R7 may form a cyclopropyl ring] were prepared as potent cytotoxins. Peptidyl and disulfide linkers are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. Thus, compound II was prepared via acylation of the 5-amino-2-benzoyl intermediate. Comps. I generally have an IC₅₀ value in a proliferation assay of .apprx. 1-100 nM, preferably .apprx. 10-10 nM.

IT 477207-78-6P 477207-81-1P 477207-82-2P
 477207-83-3P 477207-84-4P 477207-86-6P
 477209-21-5P 477209-22-6P 477209-52-2P
 477209-54-4P 477209-56-6P 477209-59-9P
 477209-60-2P 477209-61-3P 477209-62-4P
 477209-63-5P 477209-64-6P 477209-66-8P
 477209-67-9P 477209-68-0P 477209-69-1P
 477328-57-7P 477328-58-8P 477328-60-2P
 477328-61-3P 477328-62-4P 477328-63-5P
 477328-64-6P



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of duocarmycin analogs as potent cytotoxins)

RN 477207-78-6 HCAPLUS

CN L-Leucinamide, β-alanyl-L-leucyl-L-alanyl-N-[2-[[[(8S)-8-(chloromethyl)-3,6,7,8-tetrahydro-1-(methoxycarbonyl)-2-methyl-6-[(5-nitro-2-benzofuranyl)carbonyl]benzo[1,2-b:4,3-b']dipyrrol-4-yl]oxy]carbonyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 477207-81-1 HCAPLUS

CN L-Leucinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl-N-[2-[[[[(8S)-8-(chloromethyl)-3,6,7,8-tetrahydro-1-(methoxycarbonyl)-2-methyl-6-[(5-nitro-2-benzofuranyl)carbonyl]benzo[1,2-b:4,3-b']dipyrrol-4-yl]oxy]carbonyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 477207-82-2 HCAPLUS

CN L-Leucinamide, β -alanyl-L-leucyl-L-alanyl-L-leucyl-N-[2-[[[(8S)-8-(chloromethyl)-3,6,7,8-tetrahydro-1-(methoxycarbonyl)-2-methyl-6-[(5-nitro-2-benzofuranyl)carbonyl]benzo[1,2-b:4,3-b']dipyrrol-4-yl]oxy]carbonyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 477207-83-3 HCAPLUS

CN Glycinamide, β -alanyl-L-leucyl-L-alanyl-N-[2-[[[(8S)-8-(chloromethyl)-3,6,7,8-tetrahydro-1-(methoxycarbonyl)-2-methyl-6-[(5-nitro-2-benzofuranyl)carbonyl]benzo[1,2-b:4,3-b']dipyrrol-4-yl]oxy]carbonyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 477207-84-4 HCAPLUS

CN L-Leucinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- β -alanyl-L-leucyl-L-alanyl-N-[2-[[[(8S)-8-(chloromethyl)-6-[[5-[2-(dimethylamino)ethoxy]-2-benzofuranyl]carbonyl]-3,6,7,8-tetrahydro-1-(methoxycarbonyl)-2-methylbenzo[1,2-b:4,3-b']dipyrrol-4-yl]oxy]carbonyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 477207-86-6 HCAPLUS

CN L-Leucinamide, β -alanyl-L-leucyl-L-alanyl-N-[2-[[[(8S)-8-(chloromethyl)-6-[[5-[2-(dimethylamino)ethoxy]-2-benzofuranyl]carbonyl]-3,6,7,8-tetrahydro-1-(methoxycarbonyl)-2-methylbenzo[1,2-b:4,3-b']dipyrrol-4-yl]oxy]carbonyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 477209-21-5 HCAPLUS

CN L-Leucinamide, β -alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 477209-22-6 HCAPLUS


CN L-Leucinamide, N-[1,4-dioxo-4-(phenylmethoxy)butyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-8-cyano-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 477209-52-2 HCAPLUS

CN L-Leucinamide, N-[1,4-dioxo-4-(phenylmethoxy)butyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,6-dihydro-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 477209-54-4 HCAPLUS

CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,6-dihydro-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 477209-56-6 HCAPLUS


CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)- β -alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 477209-59-9 HCAPLUS


CN L-Leucinamide, N-(5-carboxy-1-oxopentyl)- β -alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[[4-methyl-1-piperazinyl]carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 477209-60-2 HCAPLUS


CN L-Leucinamide, N-(6-methoxy-1,6-dioxohexyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 477209-61-3 HCAPLUS


CN L-Leucinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[4-methyl-1-piperazinyl]carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuran]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 477209-62-4 HCAPLUS


CN L-Leucinamide, N-[1,6-dioxo-6-(phenylmethoxy)hexyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[[4-methyl-1-piperazinyl]carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 477209-63-5 HCAPLUS


CN L-Leucinamide, N-[1,4-dioxo-4-(phenylmethoxy)butyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[4-methyl-1-piperazinyl]carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 477209-64-6 HCAPLUS


CN L-Leucinamide, N-(5-carboxy-1-oxopentyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 477209-66-8 HCAPLUS


CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[2-[[[1S]-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A





RN 477209-67-9 HCAPLUS

CN L-Leucinamide, β -alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 477209-68-0 HCAPLUS

CN L-Leucinamide, N-[(1-methyl-4-piperidinyl)carbonyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477209-69-1 HCAPLUS


CN L-Leucinamide, β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 477328-57-7 HCAPLUS


CN Leucinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- β -
alanylleucylalanyl-N-[2-[[[[(8S)-8-(chloromethyl)-3,6,7,8-tetrahydro-6-[(5-
methoxy-2-benzofuranyl)carbonyl]-1-(methoxycarbonyl)-2-methylbenzo[1,2-
b:4,3-b']dipyrrol-4-yl]oxy]carbonyl]ethylamino]ethyl]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 477328-58-8 HCAPLUS


CN Leucinamide, N-[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]-
 β -alanylleucylalanyl-N-[2-[[[(8S)-8-(chloromethyl)-3,6,7,8-
tetrahydro-6-[(5-methoxy-2-benzofuranyl)carbonyl]-1-(methoxycarbonyl)-2-
methylbenzo[1,2-b:4,3-b']dipyrrol-4-yl]oxy]carbonyl]ethylamino]ethyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 477328-60-2 HCAPLUS


CN Leucinamide, β -alanylleucylalanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






PAGE 1-B



RN 477328-61-3 HCAPLUS

CN Leucinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- β -alanylleucylalanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry:




RN 477328-62-4 HCAPLUS


CN Leucinamide, β -alanylleucylalanyl-N-[2-[[[2-[[[2-(8bR, 9aS)-9, 9a-dihydro-4-oxo-1H-benzo[e]cycloprop[c]indol-2(4H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 477328-63-5 HCAPLUS

CN Leucinamide, β -alanylleucylalanyl-N-[2-[[[2-[[[1S]-1-(chloromethyl)-8-cyano-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 477328-64-6 HCAPLUS

CN Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanylleucylalanyl-N-[6-[[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]amino]-6-oxohexyl]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:755199 HCAPLUS Full-text

DOCUMENT NUMBER: 137:284323

TITLE: Enzyme-cleavable prodrug compounds

INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar,

Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
 PATENT ASSIGNEE(S): Belg.
 SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
 US 1998-111793P P 19981211
 US 1999-119312P P 19990208
 WO 1999-US30393 A2 19991210
 US 2000-211887P P 20000614
 US 2001-290448P P 20010511

OTHER SOURCE(S): MARPAT 137:284323

AB The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.


IT 274912-87-7P 274912-88-8P 274912-89-9P

RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (thimet oligopeptidase-cleavable prodrug compds.)


RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 274912-88-8 HCAPLUS

CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 274912-89-9 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 177953-52-5P 274912-90-2P 274912-91-3P
 274912-92-4P 274912-93-5P 274912-94-6P
 274912-95-7P 274912-96-8P 274912-97-9P
 274912-99-1P 274913-02-9P 274913-03-0P

274913-04-1P 274913-05-2P 274913-06-3P

274913-07-4P


RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified);
THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(thimet oligopeptidase-cleavable prodrug compds.)


RN 177953-52-5 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[(β -alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 274912-90-2 HCAPLUS


CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(triphenylmethyl)- β -alanyl-L-leucyl-L-alanyl-L-leucyl]amino]- α -L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 274912-91-3 HCAPLUS

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(diphenylmethyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxohexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 274912-92-4 HCAPLUS

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[(phenylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-93-5 HCAPLUS

CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-94-6 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-95-7 HCAPLUS

CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)- β -alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-96-8 HCAPLUS

CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)- β -alanyl-L-leucyl-L-alanyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-97-9 HCAPLUS

CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 274912-99-1 HCAPLUS


CN 5,12-Naphthacenedione, 8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[[2,3,6-trideoxy-3-[[N-[(9H-fluoren-9-ylmethoxy)carbonyl]- β -alanyl-L-leucyl-L-alanyl-L-leucyl]amino]- α -L-lyxohexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274913-02-9 HCAPLUS


CN Propanoic acid, 2-hydroxy-, compd. with (8S,10S)-10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 177953-52-5

CMF C45 H61 N5 O15

Absolute stereochemistry.




PAGE 1-B



CM 2

CRN 50-21-5

CMF C3 H6 O3




RN 274913-03-0 HCAPLUS

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[N-[1,4-dioxo-4-(2-


propenyloxy)butyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 274913-04-1 HCAPLUS

CN L-Leucine, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274913-05-2 HCAPLUS

CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 274913-06-3 HCAPLUS


CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 274913-07-4 HCAPLUS

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 177953-71-8P 274911-87-4P 274911-89-6P
 274911-90-9P 274911-91-0P 274911-93-2P
 274911-94-3P 274911-96-5P 274911-98-7P
 274912-01-5P 274912-03-7P 274912-05-9P
 274912-06-0P 274912-08-2P 274912-09-3P
 274912-12-8P 274912-13-9P 274912-15-1P
 274912-17-3P 274912-19-5P 274912-20-8P
 274912-34-4P 274912-35-5P 274912-36-6P
 274912-39-9P 274912-44-6P 274912-47-9P
 274912-49-1P 274912-50-4P 274912-52-6P
 274912-55-9P 274912-56-0P 274912-57-1P
 274912-62-8P 274912-73-1P 274912-74-2P
 274912-75-3P 274912-77-5P 274912-78-6P
 274912-79-7P 274912-82-2P 274912-86-6P
 381232-52-6P 381232-53-7P 381232-57-1P
 381232-63-9P 381232-64-0P 381232-71-9P
 381232-73-1P 381232-74-2P 381232-75-3P

RL: PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (thimet oligopeptidase-cleavable prodrug compds.)

RN 177953-71-8 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-87-4 HCAPLUS

CN L-Leucine, β -alanyl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-89-6 HCAPLUS

CN L-Leucine, β -alanyl-L-alanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-90-9 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-91-0 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-phenylalanyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-93-2 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-94-3 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-96-5 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-98-7 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-01-5 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-03-7 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-leucyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-05-9 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-06-0 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-seryl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-08-2 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-09-3 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-leucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-12-8 HCAPLUS

CN L-Leucine, β -alanyl-L-leucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-13-9 HCAPLUS

CN L-Leucine, 2-methylalanyl-L-leucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-15-1 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-17-3 HCAPLUS

CN L-Alanine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-19-5 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


9



RN 274912-20-8 HCAPLUS

CN Glycine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-34-4 HCAPLUS

CN L-Tyrosine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-35-5 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-36-6 HCAPLUS

CN L-Leucine, β -alanyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-39-9 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-methionyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-44-6 HCAPLUS

CN L-Leucine, β -alanyl-L-methionyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-47-9 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-49-1 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-50-4 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-norleucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-52-6 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-55-9 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-56-0 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-norleucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-57-1 HCAPLUS

CN L-Leucine, β -alanyl-L-norvalyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-62-8 HCAPLUS

CN L-Leucine, β -alanyl-L-prolyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-73-1 HCAPLUS

CN L-Leucine, β -alanyl-L-valyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-74-2 HCAPLUS

CN L-Leucine, β -alanyl-L-tryptophyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-75-3 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-tyrosyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-77-5 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-78-6 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-79-7 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-82-2 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-86-6 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-52-6 HCAPLUS

CN L-Leucine, D-alanyl-3-(2-thienyl)-L-alanyl- β -alanyl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

— Bu-i

RN 381232-53-7 HCAPLUS

CN L-Leucine, 3-(2-thienyl)-L-alanyl- β -alanyl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

— Bu-i

RN 381232-57-1 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-3-(3-pyridinyl)-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-63-9 HCAPLUS

CN L-Alanine, β -alanyl-L-leucyl-L-alanyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-64-0 HCAPLUS

CN L-Serine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-71-9 HCAPLUS

CN L-Leucine, β -alanyl-4-chloro-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-73-1 HCAPLUS

CN L-Leucine, β -alanyl-4-nitro-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-74-2 HCAPLUS

CN L-Leucine, β -alanyl-(2S)-2-phenylglycyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-75-3 HCAPLUS

CN L-Leucine, β -alanyl-3-(3-pyridinyl)-L-alanyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:10314 HCAPLUS Full-text

DOCUMENT NUMBER: 136:86054

TITLE: Tripeptide prodrug compounds

INVENTOR(S): Bebbington, Christopher R.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 102 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000263	A2	20020103	WO 2001-US40925	20010611
WO 2002000263	A3	20020815		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2411545	AA	20020103	CA 2001-2411545	20010611
EP 1294403	A2	20030326	EP 2001-942249	20010611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004501875	T2	20040122	JP 2002-505044	20010611
US 2003181359	A1	20030925	US 2002-311519	20021213
PRIORITY APPLN. INFO.: US 2000-212880P P 20000614				
WO 2001-US40925 W 20010611				

OTHER SOURCE(S): CASREACT 136:86054; MARPAT 136:86054

AB The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide AA3-AA2-AA1 (AA1 is leucine, phenylalanine, isoleucine, alanine, glycine, tyrosine, 2-naphthylalanine, or serine; AA2 is alanine, leucine, tyrosine, glycine, serine, 3-pyridylalanine, 2-thienylalanine, aminoisobutyric acid, threonine, or phenylalanine; AA3 is leucine, sarcosine, tyrosine, phenylalanine, p-chloro- or p-nitrophenylalanine, valine, norleucine, norvaline, phenylglycine, tryptophan, tetrahydroisoquinoline-3-carboxylic acid, 3-pyridylalanine, alanine, glycine, 2-thienylalanine, methionine, or proline), a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Thus, Suc-Leu-Ala-Leu-Dox (Suc = succinic acid residue, Dox = doxorubicin residue), prepared by conjugation of doxorubicin hydrochloride with Fmoc-Leu-Ala-Leu-OH, deprotection, and acylation with succinic anhydride, showed tumor-activated prodrug activity on LNCaP, HT-29 and PC-3 cells of 0.016, 0.052, and 0.075 μ M, resp. Suc-Leu-Ala-Leu-Dox is better tolerated in vivo than is doxorubicin.

IT 274912-87-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tripeptide prodrug compds.)


RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)- β -alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



L7 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:923644 HCAPLUS Full-text
 DOCUMENT NUMBER: 136:58787
 TITLE: Enzyme-cleavable prodrug compounds
 INVENTOR(S): Nieder, Matthew H.; Dubois, Vincent; Gangwar, Sanjeev;
 Lobl, Thomas J.; Pickford, Leslie B.; Trouet, Andre;
 Yarranton, Geoffrey T.
 PATENT ASSIGNEE(S): Corixa Corporation, USA
 SOURCE: PCT Int. Appl., 159 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095945	A2	20011220	WO 2001-US18903	20010611
WO 2001095945	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2411660 AA 20011220 CA 2001-2411660 20010611
 EP 1294405 A2 20030326 EP 2001-950291 20010611
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004510703 T2 20040408 JP 2002-510122 20010611
 PRIORITY APPLN. INFO.: US 2000-211887P P 20000614
 US 2001-290448P P 20010511
 WO 2001-US18903 W 20010611

OTHER SOURCE(S): MARPAT 136:58787

AB The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme, thimet oligopeptidase (TOP). Also disclosed are methods of designing prodrugs by utilizing TOP-cleavage sequences within the conjugate and methods of treating patients with prodrugs of the invention.

IT 177953-71-8DP, drug conjugates 274911-87-4DP, drug conjugates 274911-89-6DP, drug conjugates 274911-90-9DP, drug conjugates 274911-91-0DP, drug conjugates 274911-93-2DP, drug conjugates 274911-94-3DP, drug conjugates 274911-96-5DP, drug conjugates 274911-98-7DP, drug conjugates 274912-01-5DP, drug conjugates 274912-03-7DP, drug conjugates 274912-05-9DP, drug conjugates 274912-06-0DP, drug conjugates 274912-08-2DP, drug conjugates 274912-09-3DP, drug conjugates 274912-12-8DP, drug conjugates 274912-13-9DP, drug conjugates 274912-15-1DP, drug conjugates 274912-17-3DP, drug conjugates 274912-19-5DP, drug conjugates 274912-20-8DP, drug conjugates 274912-34-4DP, drug conjugates 274912-35-5DP, drug conjugates 274912-36-6DP, drug conjugates 274912-39-9DP, drug conjugates 274912-44-6DP, drug conjugates 274912-47-9DP, drug conjugates 274912-49-1DP, drug conjugates 274912-50-4DP, drug conjugates 274912-52-6DP, drug conjugates 274912-55-9DP, drug conjugates 274912-56-0DP, drug conjugates 274912-57-1DP, drug conjugates 274912-62-8DP, drug conjugates 274912-73-1DP, drug conjugates 274912-74-2DP, drug conjugates 274912-75-3DP, drug conjugates 274912-77-5DP, drug conjugates 274912-78-6DP, drug conjugates 274912-79-7DP, drug conjugates 274912-82-2DP, drug conjugates 274912-86-6DP, drug conjugates 274912-87-7P 274912-88-8P 274912-89-9P 381232-52-6DP, drug conjugates 381232-53-7DP, drug conjugates 381232-57-1DP, drug conjugates 381232-63-9DP, drug conjugates 381232-64-0DP, drug conjugates 381232-71-9DP, drug conjugates 381232-73-1DP, drug conjugates 381232-74-2DP, drug conjugates 381232-75-3DP, drug conjugates


RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(enzyme-cleavable prodrug compds.)

RN 177953-71-8 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-87-4 HCAPLUS

CN L-Leucine, β -alanyl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-89-6 HCAPLUS

CN L-Leucine, β -alanyl-L-alanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-90-9 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-91-0 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-phenylalanyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-93-2 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-94-3 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-96-5 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-98-7 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-01-5 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-03-7 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-leucyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-05-9 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-06-0 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-seryl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-08-2 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-09-3 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-leucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-12-8 HCAPLUS

CN L-Leucine, β -alanyl-L-leucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-13-9 HCAPLUS

CN L-Leucine, 2-methylalanyl-L-leucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-15-1 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-17-3 HCAPLUS

CN L-Alanine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-19-5 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-20-8 HCAPLUS

CN Glycine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-34-4 HCAPLUS

CN L-Tyrosine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-35-5 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-36-6 HCAPLUS

CN L-Leucine, β -alanyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-39-9 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-methionyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-44-6 HCAPLUS

CN L-Leucine, β -alanyl-L-methionyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-47-9 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-49-1 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-50-4 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-norleucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-52-6 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-55-9 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-56-0 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-norleucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-57-1 HCAPLUS

CN L-Leucine, β -alanyl-L-norvalyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-62-8 HCAPLUS

CN L-Leucine, β -alanyl-L-prolyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-73-1 HCAPLUS

CN L-Leucine, β -alanyl-L-valyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-74-2 HCAPLUS

CN L-Leucine, β -alanyl-L-tryptophyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-75-3 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-tyrosyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-77-5 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-78-6 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-79-7 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-82-2 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-86-6 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 274912-88-8 HCAPLUS


CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 274912-89-9 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 381232-52-6 HCAPLUS

CN L-Leucine, D-alanyl-3-(2-thienyl)-L-alanyl- β -alanyl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Bu-i

RN 381232-53-7 HCAPLUS

CN L-Leucine, 3-(2-thienyl)-L-alanyl- β -alanyl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




— Bu-i

RN 381232-57-1 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-3-(3-pyridinyl)-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-63-9 HCAPLUS

CN L-Alanine, β -alanyl-L-leucyl-L-alanyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-64-0 HCAPLUS

CN L-Serine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-71-9 HCAPLUS

CN L-Leucine, β -alanyl-4-chloro-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-73-1 HCAPLUS

CN L-Leucine, β -alanyl-4-nitro-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-74-2 HCAPLUS

CN L-Leucine, β -alanyl-(2S)-2-phenylglycyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 381232-75-3 HCAPLUS

CN L-Leucine, β -alanyl-3-(3-pyridinyl)-L-alanyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:693138 HCAPLUS Full-text

DOCUMENT NUMBER: 135:273218

TITLE: Preparation of peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use

INVENTOR(S): Copeland, Robert A.; Albright, Charles F.; Combs, Andrew P.; Dowling, Radine L.; Graciani, Nilsa R.; Han, Wei; Higley, C. Anne; Huang, Pearl S.; Yue, Eddy W.; Dimeo, Susan V.

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 203 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	----	-----	-----
WO 2001068145	A2	20010920	WO 2001-US8589	20010315
WO 2001068145	A3	20020711		
W:	AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, IN, JP, KR, LT, LU, LV, MX, NZ, PL, PT, RO, RU, SE, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR			
CA 2401873	AA	20010920	CA 2001-2401873	20010315
US 2002103133	A1	20020801	US 2001-808832	20010315
US 6844318	B2	20050118		
EP 1263473	A2	20021211	EP 2001-918798	20010315
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY, TR			
BR 2001009266	A	20030429	BR 2001-9266	20010315
JP 2003526683	T2	20030909	JP 2001-566708	20010315
EE 200200522	A	20040415	EE 2002-522	20010315
PRIORITY APPLN. INFO.:			US 2000-189387P	P 20000315
			WO 2001-US8589	W 20010315

OTHER SOURCE(S): MARPAT 135:273218

AB This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase. The conjugated compds. are for use as chemotherapeutic agents in the targeted treatment of cancers. Claimed peptide sequences include Cap-Paa-Xa2-Gly-Xp1-Laa, where Cap is an N-terminus group R, Xa4 or R-Xa4 (R is an amino capping group, Xa4 is an amino acid), Paa is Pro, 4-hydroxyproline (Hyp), 2-carboxyazetidine (Aze), homo-Pro, cyclohexylglycine (Chg), 4-fluorophenylalanine (Fph), nipecotic acid (Npa), 4-thiazolidinecarboxylic acid (Tzc), or proline mimetic; Xa2 is an amino acid; Xp1 is an amino acid wherein -Gly-Xp1- or -Sar-Xp1 form a bond cleavable by a matrixin; Laa is an amino acid, e.g., Leu, Ile, Nle, β -homo-Leu, homoleucine, homoserine, Ala and cyclohexylalanine. Thus, peptide conjugate Ac-PLGLYL-Dox (Dox = doxorubicin) was prepared by the solid phase method and evaluated for stability in blood and cleavage with MMPs and neprilysin.

IT 360779-43-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of antineoplastic agents conjugated to enzyme-cleavable peptides)


RN 360779-43-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[(1-acetyl-L-prolyl- β -alanylglycyl-L-leucyl-L-leucyl)amino]-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



L7 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:401690 HCAPLUS Full-text

DOCUMENT NUMBER: 133:48878

TITLE: Oligopeptide prodrug compounds and process for preparation thereof

INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.

PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2354766	AA	20000615	CA 1999-2354766	19991210
EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
NZ 512171	A	20040730	NZ 1999-512171	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
PRIORITY APPLN. INFO.:				
			US 1998-111793P	P 19981211
			US 1999-119312P	P 19990208
			WO 1999-US30393	W 19991210
			US 2000-211887P	P 20000614
			US 2001-290448P	P 20010511
OTHER SOURCE(S): MARPAT 133:48878				
AB	The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme trouase. Also disclosed are processes for making the prodrug compds.			
IT	177953-71-8 274911-85-2 274911-86-3 274911-87-4 274911-89-6 274911-90-9 274911-91-0 274911-93-2 274911-94-3 274911-96-5 274911-98-7 274912-01-5 274912-03-7 274912-05-9 274912-06-0 274912-07-1 274912-08-2 274912-09-3 274912-12-8 274912-13-9 274912-15-1 274912-17-3 274912-19-5 274912-20-8 274912-32-2 274912-34-4 274912-35-5 274912-36-6 274912-39-9 274912-44-6 274912-47-9 274912-49-1 274912-50-4 274912-52-6 274912-55-9 274912-56-0 274912-57-1 274912-62-8 274912-63-9 274912-65-1 274912-66-2 274912-67-3 274912-73-1 274912-74-2 274912-75-3 274912-77-5 274912-78-6 274912-79-7 274912-82-2 274912-86-6 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (oligopeptide prodrug compds. and process for preparation thereof)			
RN	177953-71-8 HCAPLUS			
CN	L-Leucine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)			


Absolute stereochemistry.



RN 274911-85-2 HCAPLUS

CN L-Leucine, D-alanyl-3-(2-thienyl)alanyl- β -alanyl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

— Bu-i

RN 274911-86-3 HCAPLUS

CN L-Leucine, 3-(2-thienyl)alanyl- β -alanyl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




—Bu-i

RN 274911-87-4 HCAPLUS

CN L-Leucine, β -alanyl- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-89-6 HCAPLUS

CN L-Leucine, β -alanyl-L-alanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-90-9 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-91-0 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-phenylalanyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-93-2 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-94-3 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-96-5 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274911-98-7 HCAPLUS

CN L-Leucine, β -alanyl-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-01-5 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-03-7 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-leucyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-05-9 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-06-0 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-seryl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-07-1 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-3-(3-pyridinyl)alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-08-2 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-09-3 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-leucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-12-8 HCAPLUS

CN L-Leucine, β -alanyl-L-leucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-13-9 HCAPLUS

CN L-Leucine, 2-methylalanyl-L-leucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-15-1 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-17-3 HCAPLUS

CN L-Alanine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-19-5 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-20-8 HCAPLUS

CN Glycine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-32-2 HCAPLUS

CN Alanine, β -alanyl-L-leucyl-L-alanyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-34-4 HCAPLUS

CN L-Tyrosine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-35-5 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-36-6 HCAPLUS

CN L-Leucine, β -alanyl-L-methionyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-39-9 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-methionyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-44-6 HCAPLUS

CN L-Leucine, β -alanyl-L-methionyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-47-9 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-49-1 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-50-4 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-norleucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-52-6 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-55-9 HCAPLUS

CN L-Leucine, β -alanyl-L-norleucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-56-0 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-norleucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-57-1 HCAPLUS

CN L-Leucine, β -alanyl-L-norvalyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-62-8 HCAPLUS

CN L-Leucine, β -alanyl-L-prolyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-63-9 HCAPLUS

CN L-Leucine, β -alanyl-4-chlorophenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-65-1 HCAPLUS

CN L-Leucine, β -alanyl-4-nitrophenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-66-2 HCAPLUS

CN L-Leucine, β -alanyl-2-phenylglycyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-67-3 HCAPLUS

CN L-Leucine, β -alanyl-3-(3-pyridinyl)alanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-73-1 HCAPLUS

CN L-Leucine, β -alanyl-L-valyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-74-2 HCAPLUS

CN L-Leucine, β -alanyl-L-tryptophyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-75-3 HCAPLUS

CN L-Phenylalanine, β -alanyl-L-tyrosyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-77-5 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-78-6 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosyl-L-threonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-79-7 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-82-2 HCAPLUS

CN L-Leucine, β -alanyl-L-tyrosylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-86-6 HCAPLUS

CN	L-Leucine, β -alanyl-L-tyrosyl-L-alanyl-	(9CI)	(CA INDEX NAME)
----	--	-------	-----------------

Absolute stereochemistry.



IT	177953-52-5	274912-87-7	274912-88-8
	274912-89-9	274912-90-2	274912-91-3
	274912-92-4	274912-93-5	274912-94-6
	274912-95-7	274912-96-8	274912-97-9
	274912-99-1	274913-02-9	274913-03-0
	274913-04-1	274913-05-2	274913-06-3
	274913-07-4		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(oligopeptide prodrug compds. and process for preparation thereof)

RN 177953-52-5 HCAPLUS


CN 5,12-Naphthacenedione, 10-[[3-[(β -alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S) - (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 274912-88-8 HCAPLUS

CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 274912-89-9 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 274912-90-2 HCAPLUS


CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(triphenylmethyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxohexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 274912-91-3 HCAPLUS

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(diphenylmethyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxohexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 274912-92-4 HCAPLUS

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[(phenylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-93-5 HCAPLUS

CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-94-6 HCAPLUS

CN L-Leucine, β -alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-95-7 HCAPLUS

CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)- β -alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-96-8 HCAPLUS

CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)- β -alanyl-L-leucyl-L-alanyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274912-97-9 HCAPLUS

CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 274912-99-1 HCAPLUS


CN 5,12-Naphthacenedione, 8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[[2,3,6-trideoxy-3-[[N-[(9H-fluoren-9-ylmethoxy)carbonyl]- β -alanyl-L-leucyl-L-alanyl-L-leucyl]amino]- α -L-lyxohexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274913-02-9 HCAPLUS


CN Propanoic acid, 2-hydroxy-, compd. with (8S,10S)-10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 177953-52-5

CMF C45 H61 N5 O15

Absolute stereochemistry.




PAGE 1-B



CM 2

CRN 50-21-5

CMF C3 H6 O3




RN 274913-03-0 HCAPLUS

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[1,4-dioxo-4-(2-


propenyloxy)butyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 274913-04-1 HCAPLUS

CN L-Leucine, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274913-05-2 HCAPLUS

CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 274913-06-3 HCAPLUS


CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 274913-07-4 HCAPLUS

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2000:98300 HCAPLUS Full-text
 DOCUMENT NUMBER: 132:132356
 TITLE: Chemically induced intracellular hyperthermia for
 therapeutic and diagnostic use
 INVENTOR(S): Bachynsky, Nicholas; Roy, Woodie
 PATENT ASSIGNEE(S): Texas Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 149 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006143	A1	20000210	WO 1999-US16940	19990727
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO


US 1998-94286P	P 19980727
WO 1999-US16940	W 19990727

IT 171980-70-4, Trichorzin HA V

(chemical induced intracellular hyperthermia for diagnostic and therapeutic use, and use with other agents)

CN Trichorzin HA V (9CI) (CA INDEX NAME)

[illegible]
$$\begin{array}{ccccccc} \text{--- C --- CH --- Me} & & & & \text{Me} \\ || & | & & & | \\ \text{O} & \text{NH} & \text{--- C --- CH}_2\text{--- NH --- C --- C --- Me} \\ & & || & & || & | \\ & & \text{O} & & \text{O} & \text{NHAc} \end{array}$$



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:165250 HCAPLUS Full-text

DOCUMENT NUMBER: 126:154826

TITLE: Functional surrogates of analytes of interest and methods of obtaining and using same

INVENTOR(S): Lee-Own, F. Victor; Carter, John Mark

PATENT ASSIGNEE(S): Cytogen Corporation, USA

SOURCE: PCT Int. Appl., 154 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9641172	A1	19961219	WO 1996-US10498	19960607
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
AU 9662826	A1	19961230	AU 1996-62826	19960607
PRIORITY APPLN. INFO.:			US 1995-476375	A 19950607
			WO 1996-US10498	W 19960607

AB Functional surrogates are disclosed which serve as mimics of naturally occurring mols., such as analytes of interest present in a given sample. In particular, functional surrogates (including epitopes and mimetopes) of macromol. moieties, including large to medium-sized proteins, are described. The functional surrogates of the present invention are useful in a variety of diagnostic, prophylactic, and therapeutic applications. Indeed, where the detection of a macromol. moiety is hampered by its size, a functional surrogate of the present invention, serving as the mimic of the macromol. moiety, may be better suited for a given diagnostic assay. Methods of obtaining functional surrogates, various methods of their use, and compns., including kits, are also described. Accordingly, certain binding peptides, including those of a well-defined sequence, have been discovered, which can be used in a number of affinity assays, including those utilizing fluorescence polarization immunoassay (FPIA), enzyme multiplied immunoassay technique (EMIT), or cloned enzyme donor immunoassays (CEDIA), to name a few.

IT 186743-67-9P

RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)


(functional surrogates of analytes for affinity assays including immunoassays)

RN 186743-67-9 HCAPLUS


CN L-Serine, N-acetyl-L- α -aspartyl- β -alanyl-L-tyrosyl- β -alanyl-L-serylglycylglycyl-L-arginyl-L-alanyl-L-leucyl-L-phenylalanyl-L-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L7 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:377089 HCAPLUS Full-text

DOCUMENT NUMBER: 125:49345

TITLE: Compounds, pharmaceutical composition and diagnostic system comprising same, and their use

INVENTOR(S): Trouet, Andre; Baurain, Roger

PATENT ASSIGNEE(S): La Region Wallonne, Belg.; Baurain, Roger

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9605863	A1	19960229	WO 1995-BE76	19950821

W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN
 RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

BE 1008580	A3	19960604	BE 1994-751	19940819
BE 1008581	A3	19960604	BE 1994-752	19940819
CA 2203622	AA	19960229	CA 1995-2203622	19950821
AU 9532486	A1	19960314	AU 1995-32486	19950821
AU 694546	B2	19980723		
EP 769967	A1	19970502	EP 1995-928905	19950821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10508291	T2	19980818	JP 1995-507662	19950821
NO 9700748	A	19970410	NO 1997-748	19970218
US 5962216	A	19991005	US 1997-793910	19970401
US 6342480	B1	20020129	US 1999-298330	19990423
US 2002160943	A1	20021031	US 2001-12576	20011109

PRIORITY APPLN. INFO.:

BE 1994-751	A	19940819
BE 1994-752	A	19940819
WO 1995-BE76	W	19950821
US 1997-793910	A1	19970401
US 1999-298330	A1	19990423

OTHER SOURCE(S): MARPAT 125:49345

AB The compds. W-Z-M of the invention comprise an element M, selected from markers and therapeutic agents having an intracellularly active site, linked to a ligand W-Z having an arm Z linked to a terminal group W. The bond between the arm Z of the ligand W-Z and the element M prevents the compound (W-Z-M) from penetrating within the cells and/or inhibits expression of the marker M. This bond is selectively cleaved by factors secreted by target cells so as to enable the marker M to be expressed in the target cells or the therapeutic agent M to penetrate therein; the terminal group W ensures that the compound (W-Z-M) is stable in serum and circulating blood. Data are presented for e.g. effect of β -Ala-L-Leu-L-Ala-L-Leu-daunorubicin conjugate with mammary carcinoma cells. Also described is characterization of protease(s) secreted into the extracellular medium and able to hydrolyze β -Ala-Leu-Ala-Leu-doxorubicin.

IT 177953-51-4P 177953-52-5P


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (drug conjugates and marker conjugates with cleavable bond, pharmaceutical compns., and diagnostic system)

RN 177953-51-4 HCAPLUS


CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-[N-[N-(3-amino-1-oxopropyl)-L-leucyl]-L-alanyl]-L-leucyl]amino]-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 177953-52-5 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S) - (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A





IT 177953-71-8D, reaction products with coumarin
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (drug conjugates and marker conjugates with
 cleavable bond, pharmaceutical compns., and diagnostic system)
 RN 177953-71-8 HCAPLUS
 CN L-Leucine, β -alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> DIS HIST

(FILE 'HOME' ENTERED AT 14:21:22 ON 23 JUN 2005)

FILE 'REGISTRY' ENTERED AT 14:21:32 ON 23 JUN 2005

L1 3730968 S ['BAL' 'NAL' 'AIB' 'ALM'] [LYFVWMPAG 'NLE' 'NVA' 'PHG'] [LFIAGYSFT 'NAL'
 L2 98737 L1 AND SQL=<20
 L3 98737 L2 AND SQL>=4
 L4 1893 S L3 AND ['BAL' 'NAL' 'AIB'] [LYFVWMPAG 'NLE' 'NVA' 'PHG'] [LFIAGYSFT'

FILE 'HCAPLUS' ENTERED AT 14:25:19 ON 23 JUN 2005

L5 879 L4
 L6 31 L5 AND THERAPEUTIC
 L7 11 L6 AND CONJUGATE

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	78.84	145.83
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.03	-8.03

STN INTERNATIONAL LOGOFF AT 14:31:25 ON 23 JUN 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653adk

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	STN Patent Forums to be held in June 2005
NEWS	20	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	21	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	22	JUN 13	FRFULL enhanced with patent drawing images

NEWS 23 JUN 20 MEDICONF to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:07:21 ON 23 JUN 2005

=> index medicine cancer biosci -dgene

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST	0.21	0.21
---------------------	------	------

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS,
CEN, DDFB, DDFU, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE,
ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET,
LIFESCI, MEDICONF, MEDLINE, NAPRALERT, ...' ENTERED AT 17:07:38 ON 23 JUN
2005

77 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s salal (w) dox or cpi (w) 0004na

- 1 FILE ADISINSIGHT
- 7 FILE BIOSIS
- 2 FILE BIOTECHNO
- 1 FILE CANCERLIT
- 5 FILE CAPLUS
- 7 FILE DDFU
- 7 FILE DRUGU
- 4 FILE EMBASE
- 2 FILE ESBIOBASE
- 1 FILE IFIPAT
- 3 FILE MEDLINE
- 2 FILE PASCAL

32 FILES SEARCHED...

- 4 FILE SCISEARCH
- 8 FILE TOXCENTER
- 2 FILE USPATFULL
- 1 FILE PHAR

1 FILE PROMT
1 FILE PROUSDDR
1 FILE SYNTHLINE
72 FILES SEARCHED...
1 FILE WPIDS
1 FILE WPINDEX

21 FILES HAVE ONE OR MORE ANSWERS, 77 FILES SEARCHED IN STNINDEX

L1 QUE SALAL (W) DOX OR CPI (W) 0004NA

=> d rank

F1	8	TOXCENTER
F2	7	BIOSIS
F3	7	DDFU
F4	7	DRUGU
F5	5	CAPLUS
F6	4	EMBASE
F7	4	SCISEARCH
F8	3	MEDLINE
F9	2	BIOTECHNO
F10	2	ESBIOBASE
F11	2	PASCAL
F12	2	USPATFULL
F13	1	ADISINSIGHT
F14	1	CANCERLIT
F15	1	IFIPAT
F16	1	PHAR
F17	1	PROMT
F18	1	PROUSDDR
F19	1	SYNTHLINE
F20	1	WPIDS
F21	1	WPINDEX

=> fil f1-f21

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

1.77

1.98

FILE 'TOXCENTER' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 ACS

FILE 'BIOSIS' ENTERED AT 17:09:23 ON 23 JUN 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DRUGU' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CAPLUS' ENTERED AT 17:09:23 ON 23 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:09:23 ON 23 JUN 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 17:09:23 ON 23 JUN 2005

FILE 'BIOTECHNO' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'PASCAL' ENTERED AT 17:09:23 ON 23 JUN 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'USPATFULL' ENTERED AT 17:09:23 ON 23 JUN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'ADISINSIGHT' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'CANCERLIT' ENTERED AT 17:09:23 ON 23 JUN 2005

FILE 'IFIPAT' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'PHAR' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PROMT' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'SYNTHLINE' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'WPIDS' ENTERED AT 17:09:23 ON 23 JUN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> l1

L2 54 L1

=> dup rem l2

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, PHAR, PROUSDDR, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L2

L3 24 DUP REM L2 (30 DUPLICATES REMOVED)

=> d l3 1-24 ibib kwic

L3 ANSWER 1 OF 24 USPATFULL on STN DUPLICATE 1
ACCESSION NUMBER: 2005:30747 USPATFULL Full-text
TITLE: Allosteric probes and methods
INVENTOR(S): Nilsen-Hamilton, Marit, Ames, IA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005026178	A1	20050203
APPLICATION INFO.:	US 2004-809886	A1	20040326 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-457936P	20030328 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 2101 L Street, NW, Washington, DC, 20037	
NUMBER OF CLAIMS:	55	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1198	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . fluids from these cancers. PSA has been targeted with peptide-based prodrugs linked with toxic agents, doxorubicin or thapsigargin. The prodrugs CPI-0004Na and L-377202 comprise peptides linked to doxorubicin.

CLM What is claimed is:

11. The probe of claim 9, wherein the prodrug is selected from the group consisting of CPI-0004Na and L-377202.

13. The probe of claim 10, where the prodrug is selected from the group consisting of CPI-0004Na and L-377202.

34. The method of claim 32, wherein the prodrug is selected from the group consisting of CPI-0004Na and L-377202.

37. The method of claim 33, wherein the prodrug is selected from the group consisting of CPI-0004Na and L-377202.

52. The method of claim 50, wherein the prodrug is selected from the group consisting of CPI-0004Na and L-377202.

L3 ANSWER 2 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2005:81108 USPATFULL Full-text

TITLE: Targeted ligands

INVENTOR(S): Herman, William, Thornhill, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005069549	A1	20050331
APPLICATION INFO.:	US 2004-501453	A1	20041122 (10)
	WO 2003-CA44		20030114

	NUMBER	DATE
PRIORITY INFORMATION:	CA 2002-2368708	20020114
	WO 2002-CA317	20020311
	CA 2002-2397169	20020813
	CA 2002-2402930	20020919
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BERESKIN AND PARR, SCOTIA PLAZA, 40 KING STREET WEST-SUITE 4000 BOX 401, TORONTO, ON, M5H 3Y2	
NUMBER OF CLAIMS:	21	

EXEMPLARY CLAIM: 1
LINE COUNT: 9273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . US patent application 20020103133, WO02/060488, WO02/072620, WO
96105863, U.S. Pat. No. 5,962,216, WO01/95943, WO02/00263, WO01/68145,
WO01/36003, Dubois V, et al. CPI-0004Na, a new
extracellularly tumor-activated prodrug of doxorubicin: invivo toxicity,
activity, and tissue distribution confirm tumor cell selectivity. Cancer
Res. 2002. . .

L3 ANSWER 3 OF 24 TOXCENTER COPYRIGHT 2005 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2004:234181 TOXCENTER Full-text
COPYRIGHT: Copyright 2005 ACS
DOCUMENT NUMBER: CA14120325667W
TITLE: Allosteric nucleic acid probes and their use in disease
diagnosis and treatment
AUTHOR(S): Nilsen-Hamilton, Marit
CORPORATE SOURCE: ASSIGNEE: Iowa State University Research Foundation, Inc.
PATENT INFORMATION: WO 2004088279 A2 14 Oct 2004
SOURCE: (2004) PCT Int. Appl., 47 pp.
CODEN: PIXXD2.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2004:857758
LANGUAGE: English
ENTRY DATE: Entered STN: 20041019
Last Updated on STN: 20050104

RN 32986-56-4 (Tobramycin)
13981-56-1 (Fluorine-18)
14133-76-7 (Technetium-99)
207395-85-5 (L-377202)
274912-87-7 (CPI-0004Na)
57-92-1 (Streptomycin)
1404-04-2 (Neomycin)
26787-78-0 (Amoxicillin)
56-65-5 (ATP)
58-55-9 (Theophylline)
61-19-8 (AMP)
74-79-3 (Arginine)
119-04-0 (Neomycin B)
146-17-8 (FMN)
372-75-8. . .

L3 ANSWER 4 OF 24 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
ACCESSION NUMBER: 2004242318 EMBASE Full-text
TITLE: Anthracyclines: Molecular advances and pharmacologie
developments in antitumor activity and cardiotoxicity.
AUTHOR: Minotti G.; Menna P.; Salvatorelli E.; Cairo G.; Gianni L.
CORPORATE SOURCE: Dr. G. Minotti, G. d'Annunzio Univ. Sch. of Medicine,
Centro Studi sull'Invecchiamento, Via dei Vestini, 66013
Chieti, Italy. gminotti@unich.it
SOURCE: Pharmacological Reviews, (2004) Vol. 56, No. 2, pp.
185-229.
Refs: 375
ISSN: 0031-6997 CODEN: PAREAQ
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 016 Cancer

037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 20040715
 Last Updated on STN: 20040715

CT Medical Descriptors:

*cancer: . . .
 trial
 *doxorubicin: AN, drug analysis
 *doxorubicin: CB, drug combination
 *doxorubicin: CM, drug comparison
 *doxorubicin: DO, drug dose
 *doxorubicin: IT, drug interaction
 *doxorubicin: DT, drug therapy
 *doxorubicin: PK, pharmacokinetics
 *doxorubicin: PD, pharmacology
 *daunorubicin: AE, adverse drug reaction
 *daunorubicin: CT, clinical trial
 *daunorubicin: AN, drug analysis
 *daunorubicin: CR, drug concentration
 *daunorubicin: DO, drug dose
 *daunorubicin: DT, drug.
 1 yl]benzenesulfonamide: DV, drug development
 antioxidant
 iron chelate: AN, drug analysis
 razoxane: AN, drug analysis
 unindexed drug
 unclassified drug
 1,2 propanediamine n,n' diacetamide n,n' diacetic acid
 evacet
 1 377202
 cpi 0004na
 pk 2
 3' deamino 3' morpholinooxaunomycin
 mx 2
 nemorubicin
 pnu 159548
 4 demethoxy 14 hydroxydaunomycinone 7 o [4 o (3 amino 2,3,6 trideoxy alpha
 lyxo.
 CN. . . Ad 288; Ad 32; Ad 198; Men 10755; Pnu 159548; Pnu 152243; Fce 23762;
 Mx 2; Krn 8602; Pk 2; Cpi 0004na; L 377202; Tlc d 99; Daunoxome;
 Myocet; Evacet; Caelyx; Doxil; Adr 925; Adr 529; Icrf 187; Bms 184476; Sc.

L3 ANSWER 5 OF 24 TOXCENTER COPYRIGHT 2005 ACS on STN DUPLICATE 3
 ACCESSION NUMBER: 2004:210428 TOXCENTER Full-text
 COPYRIGHT: Copyright 2005 ACS
 DOCUMENT NUMBER: CA14207106748R
 TITLE: CPI-0004Na, a new doxorubicin prodrug,
 reduces growth of 3LL-H61 carcinoma lung metastases in
 C57B1/6 mice
 AUTHOR(S): Dasnols, Luc; Lebtahi, Karim; Abarca-Quinones, Jorge;
 Havaux, Nathalie; Dupont, Samuel; Dubois, Vincent; Trouet,
 Andre
 CORPORATE SOURCE: Laboratory of Cell Biology & Institut des Sciences de la
 Vie, Universite catholique de Louvain, Louvain-La-Neuve,
 B-1348, Belg..
 SOURCE: Journal of Experimental Therapeutics and Oncology, (2004)
 Vol. 4, No. 2, pp. 167-169.

CODEN: JETOFX. ISSN: 1359-4117.

COUNTRY: BELGIUM
DOCUMENT TYPE: Journal
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2004:765541
LANGUAGE: English
ENTRY DATE: Entered STN: 20040921
Last Updated on STN: 20050308

TI CPI-0004Na, a new doxorubicin prodrug, reduces growth
of 3LL-H61 carcinoma lung metastases in C57B1/6 mice
AB. . . approach developed to overcome the lack of selectivity and the side
effects responsible for the limited efficacy of chemotherapeutic agents.
CPI-0004Na, a doxorubicin (Dox) prototype prodrug of
this type, is less toxic than free Dox and showed increased efficacy
against s.c.. . . carcinoma lung metastases in mice. Our results
indicate that, Dox has no effect on the number of lung metastases while
CPI-0004Na induces a 38.3% reduction on average. When
considering the effect on the proportion of the lungs' surface covered by
metastases, Dox induces a 39% reduction while the prodrug CPI-
0004Na is about two fold more active with a 71% decrease.
RN 23214-92-8 (Doxorubicin)
274912-87-7 (CPI 0004Na)

L3 ANSWER 6 OF 24 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2003:127876 PROMT Full-text
TITLE: Anticancer Agents From Antibiotic Sources - New
Antibiotics, Analogs and Derivatives, and Targeted
Cytotoxics - a Report From New Medicine.
SOURCE: PR Newswire, (29 Apr 2003) pp. LATU12529042003.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 708

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

TX Among novel prodrugs are CPI-0004 (CPI-0004Na),
CRX-103, L-377202, etc. Novel formulations include liposome-encapsulated
doxorubicin (LED), MTC-DOX, P80DOX-NP, Resmycin, SMANCS, SYN 2002, and
Transdrug Doxorubicin.

L3 ANSWER 7 OF 24 TOXCENTER COPYRIGHT 2005 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2003:232545 TOXCENTER Full-text
COPYRIGHT: Copyright 2005 ACS
DOCUMENT NUMBER: CA14011156884M
TITLE: CD10 Is a Key Enzyme Involved in the Activation of
Tumor-activated Peptide Prodrug CPI-
0004Na and Novel Analogues: Implications for the
Design of Novel Peptide Prodrugs for the Therapy of CD10+
Tumors
AUTHOR(S): Pan, Chin; Cardarelli, Pina M.; Nieder, Matthew H.;
Pickford, Lesley B.; Gangwar, Sanjeev; King, David J.;
Yarranton, Geoffrey T.; Buckman, Dana; Roscoe, William; et
al.
CORPORATE SOURCE: Corixa Corp., South San Francisco, CA, 94080, USA.
SOURCE: Cancer Research, (2003) Vol. 63, No. 17, pp. 5526-5531.
CODEN: CNREA8. ISSN: 0008-5472.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Journal
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2003:733803

LANGUAGE: English
 ENTRY DATE: Entered STN: 20030923
 Last Updated on STN: 20040309

TI CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10+ Tumors

AB. . . the tumor environment have been explored to improve the therapeutic index of cytotoxic drugs. One such prodrug of doxorubicin (Dox), CPI-0004Na [N-succinyl- β -alanyl-L-leucyl-L-alanyl-L-leucyl-Dox (sALAL-Dox)] has been shown to have an improved antitumor efficacy profile with reduced toxicity compared with Dox in tumor xenograft models. . . we demonstrate that CD10, a cell surface metalloprotease expressed on a variety of tumor cell types, is capable of cleaving CPI-0004Na and related peptide prodrugs such as N-succinyl- β -alanyl-L-isoleucyl-L-alanyl-L-leucyl-Dox (sAIAL-Dox). This proteolytic cleavage generates leucyl-Dox, which is capable of entering cells and generating intracellular Dox. In a [3H]thymidine proliferation assay, analogs of CPI-0004Na showed a 100-300-fold increase in potency on CD10+ cells compared with CD10- cells. Cytotoxicity of CPI-0004Na was inhibited by phosphoramidon, a known inhibitor of CD10 enzymic activity. Furthermore, Chinese hamster ovary CHO-S cells, which are resistant to CPI-0004Na, could be sensitized to the cytotoxic effect of the prodrug by transfection of a CD10 cDNA. Tumor xenograft studies using. . . prostate tumor cells support the important role of CD10 in the antitumor efficacy of these prodrugs against tumors expressing CD10. CPI-0004Na and sAIAL-Dox achieved statistically significant 70% tumor growth inhibition at day 22. CD10 is expressed on many types of human. . .

ST Miscellaneous Descriptors
 metalloprotease CD10 tumor peptide prodrug CPI 0004Na

RN 81669-70-7 (Metalloprotease)
 23214-92-8 (Doxorubicin)
 274912-87-7 (CPI 0004Na)
 380861-69-8 (SAIAL-Dox)
 385449-27-4 (SLAG-Dox)

RN 70774-25-3

L3 ANSWER 8 OF 24 TOXCENTER COPYRIGHT 2005 ACS on STN DUPLICATE 5
 ACCESSION NUMBER: 2002:105095 TOXCENTER Full-text
 COPYRIGHT: Copyright 2005 ACS
 DOCUMENT NUMBER: CA13717241802R
 TITLE: CPI-0004Na, a new extracellularly tumor-activated prodrug of Doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity

AUTHOR(S): Dubois, Vincent; Dasnois, Luc; Lebtahi, Karim; Collot, Francoise; Heylen, Nathalie; Havaux, Nathalie; Fernandez, Anne-Marie; Lobl, Thomas J.; Oliyai, Cecilia; et al.

CORPORATE SOURCE: Universite Catholique de Louvain, Laboratory of Cell Biology, Louvain-la-Neuve, B-1348, Belg..

SOURCE: Cancer Research, (2002) Vol. 62, No. 8, pp. 2327-2331.
 CODEN: CNREA8. ISSN: 0008-5472.

COUNTRY: BELGIUM
 DOCUMENT TYPE: Journal
 FILE SEGMENT: CAPLUS
 OTHER SOURCE: CAPLUS 2002:323079
 LANGUAGE: English
 ENTRY DATE: Entered STN: 20020509
 Last Updated on STN: 20030624

TI CPI-0004Na, a new extracellularly tumor-activated prodrug of Doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity

AB. . . normal sensitive cells has been very active for at least 20 yr. The extracellularly tumor-activated peptidic prodrug of doxorubicin (Dox) CPI-0004Na (N-succinyl- β -alanyl-L-leucyl-L-alanyl-L-leucyl-Dox) is potentially such a treatment. Here, we report the results of lethality studies performed with this compound in the. . . data indicate that this reduced toxicity is attributable to a lower uptake of Dox in normal tissues after treatment with CPI-0004Na than after the administration of an equimolar dose of Dox·HCl. For example, heart exposure to Dox is reduced > 10-fold. Because of this reduced toxicity, higher doses of CPI-0004Na than of the parent drug could be used to treat nude mice bearing s.c. human breast (MCF-7/6) and colon (LS-174-T. . . as compared with Dox·HCl. Particularly, LS-174-T tumors that do not respond to Dox were inhibited by 68% after treatment with CPI-0004Na. Tissue distribution studies performed with MCF-7/6 tumor-bearing nude mice and comparing CPI-0004Na and Dox·HCl confirmed that the improved activity of the prodrug is actually the result of selective generation and uptake of Dox at the tumor site. Dox levels in tumor tissue were 2-fold higher after treatment with CPI-0004Na than after treatment with an equimolar dose of Dox·HCl, whereas normal tissue levels were reduced 1.4-29-fold.

L3 ANSWER 9 OF 24 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 6

ACCESSION NUMBER: 2002:554867 BIOSIS Full-text

DOCUMENT NUMBER: PREV200200554867

TITLE: Improved activity of CPI-0004Na, a new doxorubicin prodrug, in an experimental metastasis model.

AUTHOR(S): Dasnois, L. [Reprint author]; Lebtahi, K. [Reprint author]; Abarca-Quinones, J. [Reprint author]; Havaux, N. [Reprint author]; Dubois, V. [Reprint author]; Trouet, A. [Reprint author]

CORPORATE SOURCE: Laboratory of Cell Biology, Univerte Catholique de Louvain, Louvain-La-Neuve, Belgium
dasnois@bani.ucl.ac.be

SOURCE: International Journal of Cancer Supplement, (2002) No. 13, pp. 435-436. print.
Meeting Info.: 18th UICC International Cancer Congress. Oslo, Norway. June 30-July 05, 2002.
ISSN: 0898-6924.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 30 Oct 2002

Last Updated on STN: 30 Oct 2002

TI Improved activity of CPI-0004Na, a new doxorubicin prodrug, in an experimental metastasis model.

IT . . .
respiratory system

IT Diseases
lung metastasis: neoplastic disease, respiratory system disease
Lung Neoplasms (MeSH); Neoplasm Metastasis (MeSH)

IT Chemicals & Biochemicals
CPI-0004Na: antineoplastic, efficacy,
pharmacokinetics, prodrug; doxorubicin: antineoplastic-drug,
pharmacokinetics

L3 ANSWER 10 OF 24 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2002-32086 DRUGU P Full-text
 TITLE: Improved activity of CPI-0004Na, a new doxorubicin prodrug, in an experimental metastasis model.
 AUTHOR: Dasnois L; Lebtahi K; Abarea Quinones J; Havaux N; Dubois V; Trouet A
 CORPORATE SOURCE: Univ.Louvain-Cath.
 LOCATION: Louvain La Neuve, Belg.
 SOURCE: Int.J.Cancer (Suppl. 13, 435-36, 2002) 3 Ref.
 CODEN: IJCNAW ISSN: 0020-7136
 AVAIL. OF DOC.: Universte Catholique de Louvain, Laboratory of Cell Biology, Louvain-La-Neuve, Belgium. (e-mail: dasnois@bani.ucl.ac.be).
 LANGUAGE: English
 DOCUMENT TYPE: Journal
 FIELD AVAIL.: AB; LA; CT
 FILE SEGMENT: Literature
 TI Improved activity of CPI-0004Na, a new doxorubicin prodrug, in an experimental metastasis model.
 AB. . . developed to overcome the lack of selectivity and the side-effects responsible for the limited efficacy of the chemotherapeutic agents. Here, CPI-0004Na, a doxorubicin (DOX) prototype prodrug of this type, was evaluated in comparison with DOX against experimentally induced lung metastases in. . . .
 ABEX. . . the lungs' surface area occupied by metastases were determined. DOX had no effect on the number of lung metastases, while CPI-0004Na induced a 38,3% reduction. When considering the effect on the proportion of the lungs' surface covered by metastases, DOX induced.

L3 ANSWER 11 OF 24 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2001-42169 DRUGU C P S Full-text
 TITLE: N-succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl) doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity.
 AUTHOR: Fernandez A M; Van derpoorten K; Dasnois L; Lebtahi K; Dubois V; Lobl T J; Gangwar S; Oliyai C; Lewis E R; Shochat D
 CORPORATE SOURCE: Univ.Louvain-Cath.; Corixo
 LOCATION: Louvain, Belg.; South San Francisco, Cal., USA
 SOURCE: J.Med.Chem. (44, No. 22, 3750-53, 2001) 1 Fig. 2 Tab. 13 Ref.
 CODEN: JMCMAR ISSN: 0022-2623
 AVAIL. OF DOC.: Laboratory of Cell Biology, Universite Catholique de Louvain, Place Croix du Sud 5, B-1348 Louvain-la-Neuve, Belgium. (11 authors). (e-mail: fernandez@bani.ucl.ac.be).
 LANGUAGE: English
 DOCUMENT TYPE: Journal
 FIELD AVAIL.: AB; LA; CT
 FILE SEGMENT: Literature
 AB. . . pH, combined with its tendency to form large aggregates in aqueous solution. The negatively charged N-capped succinyl analog of (4), CPI-0004Na (5) was nontoxic given i.v., and was active i.p. vs. MCF-7/6 mamma tumor xenografts in mice.

L3 ANSWER 12 OF 24 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 7
 ACCESSION NUMBER: 2001:435354 BIOSIS Full-text
 DOCUMENT NUMBER: PREV200100435354
 TITLE: Optimization of peptide prodrug structure with a cancer cell peptidase enzyme screen.
 AUTHOR(S): Nieder, Matthew [Reprint author]; Lobl, Tom; Nguyen, Thi;

Dubois, Vincent; Trouet, Andre; Horgan, Killian; Gangwar, Sanjeev
CORPORATE SOURCE: Coulter Pharmaceutical, Inc., South San Francisco, CA, USA
SOURCE: Proceedings of the American Association for Cancer Research
Annual Meeting, (March, 2001) Vol. 42, pp. 326. print.
Meeting Info.: 92nd Annual Meeting of the American
Association for Cancer Research. New Orleans, LA, USA.
March 24-28, 2001. American Association for Cancer
Research.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 12 Sep 2001
Last Updated on STN: 22 Feb 2002

IT . . .
Pharmacology; Tumor Biology
IT Parts, Structures, & Systems of Organisms
blood: blood and lymphatics; cancer cell
IT Chemicals & Biochemicals
CPI-0004Na: antineoplastic-drug, activation,
peptide prodrug, pharmacokinetics; cellular endopeptidase; doxorubicin:
antineoplastic-drug, sugar moiety

L3 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:202127 CAPLUS Full-text
TITLE: Sythesis OF CPI-0004Na, a
doxorubicin tap prodrug
AUTHOR(S): Gangwar, Sanjeev; Lewis, Evan; Viski, Peter; Lobl,
Tom; Trouet, Andre; Van Derpooten, Kim; Dubois,
Vincent; Fernandez, A. M.
CORPORATE SOURCE: Dept. of Medicinal Chemistry, Coulter Pharmaceuticals,
South San Francisco, CA, 94080, USA
SOURCE: Abstracts of Papers, 221st ACS National Meeting, San
Diego, CA, United States, April 1-5, 2001 (2001)
MEDI-223
CODEN: 69FZD4
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal; Meeting Abstract
LANGUAGE: English

TI Sythesis OF CPI-0004Na, a doxorubicin tap prodrug
AB Many anti-tumor agents such as anthracyclines and vinca alkaloids have been
developed in the last few years that are especially effective for the
treatment of cancer cells. However, these mols. are often characterized in
vivo by acute toxicity, especially marrow and chronic cardiac toxicity in the
case of anthracyclines and a chronic neurol. toxicity in the case of the vinca
alkaloids. CPI-0004Na is tumor activated peptide (TAP) prodrug of doxorubicin
that is stable in blood and activated in the vicinity of tumors. CPI-0004Na
is activated selectively in tumors in a MCF7 human tumor xenograft model
thereby increasing its therapeutic index. As a result it can be given at a
higher dose than doxorubicin and is effective in doxorubicin resistant tumors.
The design and the synthesis of CPI-0004Na, a new TAP anticancer therapeutic,
is presented.

L3 ANSWER 14 OF 24 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on
STN

ACCESSION NUMBER: 2001:658535 SCISEARCH Full-text
THE GENUINE ARTICLE: 434PJ
TITLE: Synthesis of CPI-0004Na, a doxorubicin

TAP prodrug.
AUTHOR: Gangwar S (Reprint); Lewis E; Viski P; Lobl T; Trouet A; Van Derpooten K; Dubois V; Fernandez A M
CORPORATE SOURCE: Coulter Pharmaceut, Dept Med Chem, S San Francisco, CA 94080 USA; Coulter Pharmaceut, Chem, S San Francisco, CA USA; Coulter Pharmaceut, Cell Biol, S San Francisco, CA USA
COUNTRY OF AUTHOR: USA
SOURCE: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, (1 APR 2001) Vol. 221, Part 2, pp. U39-U39. MA 223-MEDI. Publisher: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA. ISSN: 0065-7727.
DOCUMENT TYPE: Conference; Journal
LANGUAGE: English
REFERENCE COUNT: 0
TI Synthesis of CPI-0004Na, a doxorubicin TAP prodrug.

L3 ANSWER 15 OF 24 TOXCENTER COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:92575 TOXCENTER Full-text
COPYRIGHT: Copyright 2005 ACS
TITLE: Sythesis OF CPI-0004Na, a doxorubicin tap prodrug
AUTHOR(S): Gangwar, Sanjeev; Lewis, Evan; Viski, Peter; Lobl, Tom; Trouet, Andre; Van Derpooten, Kim; Dubois, Vincent; Fernandez, A. M.
CORPORATE SOURCE: Dept. of Medicinal Chemistry, Coulter Pharmaceuticals, South San Francisco, CA, 94080, USA.
SOURCE: Abstracts of Papers, 221st ACS National Meeting, San Diego, CA, United States, April 1-5, 2001, (2001) pp. MEDI-223. CODEN: 69FZD4.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Journal
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2001:202127
LANGUAGE: English
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20040921
TI Sythesis OF CPI-0004Na, a doxorubicin tap prodrug
AB. . . chronic cardiac toxicity in the case of anthracyclines and a chronic neurol. toxicity in the case of the vinca alkaloids. CPI-0004Na is tumor activated peptide (TAP) prodrug of doxorubicin that is stable in blood and activated in the vicinity of tumors. CPI-0004Na is activated selectively in tumors in a MCF7 human tumor xenograft model thereby increasing its therapeutic index. As a result. . . given at a higher dose than doxorubicin and is effective in doxorubicin resistant tumors. The design and the synthesis of CPI-0004Na, a new TAP anticancer therapeutic, is presented.

L3 ANSWER 16 OF 24 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:297203 BIOSIS Full-text
DOCUMENT NUMBER: PREV200100297203
TITLE: Synthesis of CPI-0004Na, a doxorubicin tap prodrug.
AUTHOR(S): Gangwar, Sanjeev [Reprint author]; Lewis, Evan; Viski, Peter; Lobi, Tom; Trouet, Andre; Van Derpooten, Kim; Dubois, Vincent; Fernandez, A. M.

CORPORATE SOURCE: Dept. of Medicinal Chemistry, Coulter Pharmaceuticals, 600 Gateway Blvd., South San Francisco, CA, 94080, USA
Sanjeev_Gangwar@Coulterpharm.com

SOURCE: Abstracts of Papers American Chemical Society, (2001) Vol. 221, No. 1-2, pp. MEDI 223. print.
Meeting Info.: 221st National Meeting of the American Chemical Society. San Diego, California, USA. April 01-05, 2001. American Chemical Society.
CODEN: ACSRAL. ISSN: 0065-7727.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 20 Jun 2001
Last Updated on STN: 19 Feb 2002

TI Synthesis of CPI-0004Na, a doxorubicin tap prodrug.

IT Major Concepts
Pharmacology; Tumor Biology

IT Chemicals & Biochemicals
CPI-0004Na: doxorubicin tumor activated peptide
(TAP) prodrug

L3 ANSWER 17 OF 24 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2000:235859 BIOSIS Full-text

DOCUMENT NUMBER: PREV200000235859

TITLE: Pharmacokinetics and tissue distribution of CPI-0004Na, a new prodrug of doxorubicin, in normal and tumor-bearing mice.

AUTHOR(S): Dubois, Vincent [Reprint author]; Fernandez, A. M.; Dasnois, L.; Collot, F.; Heylen, N.; Lobl, T.; Oliyai, C.; Shochat, D.; Trouet, A.

CORPORATE SOURCE: Coulter Pharm Inc, South San Francisco, CA, USA

SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2000) No. 41, pp. 523. print.
Meeting Info.: 91st Annual Meeting of the American Association for Cancer Research. San Francisco, California, USA. April 01-05, 2000.
ISSN: 0197-016X.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 7 Jun 2000
Last Updated on STN: 5 Jan 2002

TI Pharmacokinetics and tissue distribution of CPI-0004Na, a new prodrug of doxorubicin, in normal and tumor-bearing mice.

IT Major Concepts
Pharmacology; Tumor Biology

IT Chemicals & Biochemicals
CPI-0004NA: antineoplastic-drug, doxorubicin prodrug, efficacy, pharmacokinetics, tissue distribution; doxorubicin: antineoplastic-drug

L3 ANSWER 18 OF 24 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2000-32080 DRUGU P Full-text

TITLE: Pharmacokinetics and tissue distribution of CPI-0004NA, a new prodrug of doxorubicin, in normal and tumor-bearing mice.

AUTHOR: Dubois V; Fernandez A M; Dasnois L; Collot F; Heylen N; Lobl T; Oliyai C; Shochat D; Trouet A

CORPORATE SOURCE: Coulter; Univ.Catholique-Louvain

LOCATION: South San Francisco, Cal., USA; Louvain, Belg.
SOURCE: Proc.Am.Assoc.Cancer Res. (41, 91 Meet., 523, 2000) ISS
N: 0197-016X
AVAIL. OF DOC.: Coulter Pharma Inc., S. San Francisco, CA, U.S.A.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
FILE SEGMENT: Literature

TI Pharmacokinetics and tissue distribution of CPI-0004NA
, a new prodrug of doxorubicin, in normal and tumor-bearing mice.
AB Pharmacokinetics and tissue distribution of CPI-0004Na, an extracellularly
tumor-activated prodrug of doxorubicin (DOX), were evaluated in comparison
with DOX, i.v. administered at equimolar doses in normal. . . that of DOX.
Intact prodrug was the major species in plasma. Normal tissue exposure (AUC)
to DOX after treatment with CPI-0004Na was much reduced cf. that after DOX
(e.g. 90-95% reduction in the heart). Tumor AUC, however, was almost
doubled. Results. . .

L3 ANSWER 19 OF 24 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

ACCESSION NUMBER: 2000:235857 BIOSIS Full-text
DOCUMENT NUMBER: PREV200000235857
TITLE: CPI-0004Na: An extracellularly
tumor-activated prodrug of doxorubicin.
AUTHOR(S): Trouet, Andre [Reprint author]; Passioukov, A.;
Vanderpoorten, K.; Abarca-Quinones, J.; Lebtahi, K.;
Baurain, R.; Dubois, V.; Lobl, T.; Gangwar, S.; Lewis, E.;
Yarranton, G.
CORPORATE SOURCE: Coulter Pharm Inc, South San Francisco, CA, USA
SOURCE: Proceedings of the American Association for Cancer Research
Annual Meeting, (March, 2000) No. 41, pp. 522. print.
Meeting Info.: 91st Annual Meeting of the American
Association for Cancer Research. San Francisco, California,
USA. April 01-05, 2000.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 7 Jun 2000
Last Updated on STN: 5 Jan 2002

TI CPI-0004Na: An extracellularly tumor-activated prodrug
of doxorubicin.
IT Major Concepts
Pharmacology; Tumor Biology
IT Diseases
cancer: neoplastic disease
Neoplasms (MeSH)
IT Chemicals & Biochemicals
CPI-0004NA: antineoplastic-drug, tetrapeptidic
derivative

L3 ANSWER 20 OF 24 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2000-32079 DRUGU P C S Full-text
TITLE: CPI-0004NA: an extracellularly
tumor-activated prodrug of doxorubicin.
AUTHOR: Trouet A; Passioukov A; Vanderpoorten K; Abarca Quinones J;
Lebtahi K; Baurain R; Dubois V; Lobl T; Gangwar S; Lewis E;
Yarranton G
CORPORATE SOURCE: Coulter; Univ.Catholique-Louvain

LOCATION: South San Francisco, Cal., USA; Louvain, Belg.
SOURCE: Proc.Am.Assoc.Cancer Res. (41, 91 Meet., 522, 2000) ISS
N: 0197-016X
AVAIL. OF DOC.: Coulter Pharma Inc., South San Francisco, CA, U.S.A.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
FILE SEGMENT: Literature

TI CPI-0004Na: an extracellularly tumor-activated
prodrug of doxorubicin.
AB. . . well as for their reactivation by peptidases released by cancer cell
lines. Based on these simple assays, a tetrapeptide derivative,
CPI-0004Na, was selected. Lethality studies in the
mouse showed that CPI-0004Na was 4-16x less toxic
than DOX depending on the dosing route and the number of injections.
Also, the chemotherapeutic superiority of CPI-0004Na
as compared to DOX, was demonstrated in a number of human tumor xenograft
models (mammary and colon carcinomas) using different. . .

L3 ANSWER 21 OF 24 ADISINSIGHT COPYRIGHT (C) 2005 Adis Data Information BV
on STN

TX TEXT
Introduction:
Medarex and Diatos are developing a prodrug formulation of doxorubicin,
called DTS 201(CPI 0004, CPI 0004Na,
Super-Leu-Dox(TM)), using Tumour-Activated Peptide (TAP) platform
technology. DTS-201 comprises a four-amino acid peptide chemically
conjugated to the doxorubicin compound. When. . .

L3 ANSWER 22 OF 24 PHAR COPYRIGHT 2005 T&F Informa UK Ltd on STN
CN leucine-doxorubicin, Medarex
CN CPI-0004
CN CPI-0004Na
CN doxorubicin prodrug, Medarex
CN DTS-201
CN Super-Leu-Dox

L3 ANSWER 23 OF 24 PROUSDDR COPYRIGHT 2005 PROUS SCIENCE on STN
ACCESSION NUMBER: 2001:22 PROUSDDR Full-text

PROUS REFERENCES:
RefID: 613242 (Text Available)
Drug Data Report, Vol. 23, No. 6, pp 593, 2001

REFERENCE TEXT: RefID: 613242
ACTION - Tetrapeptide prodrug of doxorubicin shown to
be inactive against tumor cells in vitro (IC50 > 50
mcM) but to be selectively activated by proteolytic
cleavage in the vicinity of the tumor-resulting in
specific tumor cytotoxicity in vivo. Compound was
stable in human whole blood. It prolonged survival of
mice bearing doxorubicin-resistant colorectal
carcinoma LS174T or breast cancer MX-1 and
doxorubicin-sensitive prostate cancer LNCaP. In these
models it was significantly more effective and better
tolerated than doxorubicin.

PATENT REFERENCES:

TITLE: Prodrug cpds. and process for preparation thereof
INVENTOR(S): Trouet, A.; Lobl, T.J.; Dubois, V.; Fernandez, A.-M.;
Gangwar, S.; Lewis, E.; Nieder, M.H.; Viski, P.;
Yarranton, G.T.
PATENT ASSIGNEE(S): Corixa
PATENT INFORMATION: JP 2003518000 20030603
WO 2000033888 20000615
PRIORITY INFORMATION: US 1998-111793 19981211
US 1999-119312 19990208

TITLE: CD10-activated prodrug cpds.
INVENTOR(S): Cardarelli, P.M.; Gangwar, S.; Nieder, M.H.;
Bebbington, C.R.; Pickford, L.B.; Pan, C.
PATENT ASSIGNEE(S): Medarex
PATENT INFORMATION: EP 1404356 20040407
JP 2004537527 20041216
WO 2002100353 20021219
PRIORITY INFORMATION: US 2001-297596 20010611

REFERENCES:

- (1) RefID: 572049, Periodic Publication
"CPI-0004Na: An extracellularly tumor-activated prodrug of doxorubicin"
Trouet, A.; et al., Proc Am Assoc Cancer Res, Vol. 41, (Abst 3328),
2000
- (2) RefID: 572051, Periodic Publication
"Pharmacokinetics and tissue distribution of CPI-004Na, a new prodrug
of doxorubicin, in normal and tumor-bearing mice"
Dubois, V.; et al., Proc Am Assoc Cancer Res, Vol. 41, (Abst 3329),
2000
- (3) RefID: 612449, Periodic Publication
"Optimization of peptide prodrug structure with a cancer cell peptidase
enzyme screen"
Nieder, M.; et al., Proc Am Assoc Cancer Res, Vol. 42, (Abst 1757),
2001
- (4) RefID: 612450, Periodic Publication
"Evaluation of the pharmacokinetic properties of a doxorubicin prodrug
in female ICR (CD-1) mice following intravenous bolus administration"
Tabrizi-Fard, M.; et al., Proc Am Assoc Cancer Res, Vol. 42, (Abst
1746), 2001
- (5) RefID: 612451, Periodic Publication
"Cpi-0004, a doxorubicin prodrug that is inactive in vitro, prolongs
survival of both doxorubicin-resistant and -sensitive human
tumor-bearing"
Pan, C.; et al., Proc Am Assoc Cancer Res, Vol. 42, (Abst 1747), 2001
- (6) RefID: 613026, Congress Literature
"Synthesis of CPI-0004Na, a doxorubicin tap prodrug"
Gangwar, S.; et al., ACS Natl Meet (221st Edition), April 1 2001-April
5 2001, San Diego, (Abst MEDI 223)
- (7) RefID: 637021, Periodic Publication
"N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: An
extracellularly tumor-activated prodrug devoid of intravenous acute
toxicity"
Fernandez, A.-M.; et al., J Med Chem, Vol. 44, No. 22, pp 3750, 2001

- (8) RefID: 675195, Periodic Publication
 "CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: In vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity"
 Dubois, V.; et al., Cancer Res, Vol. 62, No. 8, pp 2327, 2002
- (9) RefID: 680141, Congress Literature
 "Improved activity of CPI-0004Na, a new doxorubicin prodrug, in an experimental metastasis model"
 Dasnois, L.; Dasnois, L.; Lebtahi, K.; Abarca-Quinones, J.; Havaux, N.; Dubois, V.; Trouet, A., UICC Int Cancer Congr (18th Edition), June 30 2002-July 5 2002, Oslo, (Abst P 958)
- (10) RefID: 757746, Periodic Publication
 "CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: Implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors"
 Pan, C.; et al., Cancer Res, Vol. 63, No. 17, pp 5526, 2003
- (11) RefID: 814512, Periodic Publication
 "Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity"
 Minotti, G.; et al., Pharmacol Rev, Vol. 56, No. 2, pp 185, 2004

CN DRUG NAME: CPI-0004
 CPI-0004Na
 CPI-004Na

L3 ANSWER 24 OF 24 SYNTHLINE COPYRIGHT 2005 PROUS SCIENCE on STN

ACCESSION NUMBER: 2002:4 SYNTHLINE

TITLE: N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: An extracellularly tumor-activated prodrug devoid of intravenous acute toxicity

AUTHOR(S): Fernandez, A.-M.; Van Derpoorten, K.; Dasnois, L.; Lebtahi, K.; Dubois, V.; Lobl, T.J.; Gangwar, S.; Oliyai, C.; Lewis, E.R.; Shochat, D.; Trouet, A.

SOURCE: J Med Chem (2001), 44(22), 3750

TITLE: Prodrug cpds. and process for preparation thereof

INVENTOR(S): Dubois, V.; Lewis, E.; Viski, P.; Gangwar, S.; Yarranton, G.T.; Nieder, M.H.; Fernandez, A.-M.; Trouet, A.; Lobl, T.J.

PATENT ASSIGNEE(S): Beckman Coulter, Inc.

PATENT INFORMATION: WO 2000033888

CN TAP-doxorubicin; Super-Leu-Dox; CPI-0004; CPI-004Na; CPI-0004Na

CN N-(N-(3-Carboxypropionyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucyl)daunorubicin sodium salt; (8S,10S)-10-(3-(N-(3-Carboxy-1-oxopropyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucylamido)-2,3,6-trideoxy-alpha-L-lyxohexopyranosyloxy)-8-(hydroxyacetyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydronaphthacene-5,12-dione sodium salt

RN 274912-87-7 (free acid)

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

121.83

123.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.73

-0.73

FILE 'REGISTRY' ENTERED AT 17:13:03 ON 23 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JUN 2005 HIGHEST RN 852803-45-3
DICTIONARY FILE UPDATES: 22 JUN 2005 HIGHEST RN 852803-45-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> S 274912-87-7/RN

L4 1 274912-87-7/RN

=> D L4 SQIDE TOTAL

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 274912-87-7 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)- β -alanyl-L-
leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy- α -L-lyxo-
hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-
1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN CPI 0004Na

CN sALAL-Dox

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 4

NTE modified (modifications unspecified)

type	location	description
uncommon	Bal-1	-
modification	Bal-1	3-carboxy-1-oxopropyl<Suc>

SEQ 1 XLAL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C49 H65 N5 O18

CI COM

SR CA


LC STN Files: CA, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

DT.CA CAPLUS document type: Journal; Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.



PAGE 1-B



10 REFERENCES IN FILE CA (1907 TO DATE)
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l4 ed

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
ED Entered STN: 06 Jul 2000

=> d his ful

(FILE 'HOME' ENTERED AT 17:07:21 ON 23 JUN 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DDFB, DDFU, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, ...' ENTERED AT 17:07:38 ON 23 JUN 2005

SEA SALAL (W) DOX OR CPI (W) 0004NA

1 FILE ADISINSIGHT
7 FILE BIOSIS
2 FILE BIOTECHNO
1 FILE CANCERLIT
5 FILE CAPLUS
7 FILE DDFU
7 FILE DRUGU
4 FILE EMBASE
2 FILE ESBIODBASE
1 FILE IFIPAT
3 FILE MEDLINE
2 FILE PASCAL
4 FILE SCISEARCH
8 FILE TOXCENTER
2 FILE USPATFULL
1 FILE PHAR
1 FILE PROMT
1 FILE PROUSDDR
1 FILE SYNTHLINE
1 FILE WPIDS
1 FILE WPINDEX

L1 QUE PLU=ON SALAL (W) DOX OR CPI (W) 0004NA

D RANK

FILE 'TOXCENTER, BIOSIS, DRUGU, CAPLUS, EMBASE, SCISEARCH, MEDLINE, BIOTECHNO, ESBIODBASE, PASCAL, USPATFULL, ADISINSIGHT, CANCERLIT, IFIPAT, PHAR, PROMT, PROUSDDR, SYNTHLINE, WPIDS' ENTERED AT 17:09:23 ON 23 JUN 2005

L2 54 SEA PLU=ON L1

L3 24 DUP REM L2 (30 DUPLICATES REMOVED)

D RANK

D L3 1-24 IBIB KWIC

FILE 'REGISTRY' ENTERED AT 17:13:03 ON 23 JUN 2005

L4 1 SEA PLU=ON 274912-87-7/RN

D L4 SQIDE TOTAL

D L4 ED

FILE HOME

FILE STNINDEX

FILE TOXCENTER

FILE COVERS 1907 TO 21 Jun 2005 (20050621/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields.
See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2005 vocabulary. See <http://www.nlm.nih.gov/mesh/> and
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html for a
description of changes.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNS) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 23 June 2005 (20050623/ED)

FILE RELOADED: 19 October 2003.

FILE DRUGU

FILE LAST UPDATED: 20 JUN 2005 <20050620/UP>

>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<

>>> THESAURUS AVAILABLE IN /CT <<<

FILE CAPLUS

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 23 Jun 2005 VOL 142 ISS 26

FILE LAST UPDATED: 22 Jun 2005 (20050622/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE EMBASE

FILE COVERS 1974 TO 16 Jun 2005 (20050616/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE SCISEARCH

FILE COVERS 1974 TO 16 Jun 2005 (20050616/ED)

FILE MEDLINE

FILE LAST UPDATED: 22 JUN 2005 (20050622/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>

http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOTECHNO

FILE LAST UPDATED: 7 JAN 2004 <20040107/UP>

FILE COVERS 1980 TO 2003.

>>> BIOTECHNO IS NO LONGER BEING UPDATED AS OF 2004 <<<

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
/CT AND BASIC INDEX <<<

FILE ESBIOBASE

FILE LAST UPDATED: 21 JUN 2005 <20050621/UP>

FILE COVERS 1994 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
/CC, /ORGN, AND /ST <<<

FILE PASCAL

FILE LAST UPDATED: 20 JUN 2005 <20050620/UP>

FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 23 Jun 2005 (20050623/PD)

FILE LAST UPDATED: 23 Jun 2005 (20050623/ED)

HIGHEST GRANTED PATENT NUMBER: US6910221

HIGHEST APPLICATION PUBLICATION NUMBER: US2005138714

CA INDEXING IS CURRENT THROUGH 23 Jun 2005 (20050623/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 23 Jun 2005 (20050623/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2005

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<

>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<

>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE ADISINSIGHT

FILE COVERS 1986 TO 16 Jun 2005 (20050616/ED)
FILE LAST UPDATED: 16 JUN 2005 (20050616/ED)

FILE CANCERLIT

FILE COVERS 1963 TO 15 Nov 2002 (20021115/ED)

On July 28, 2002, CANCERLIT was reloaded. See HELP RLOAD for details.

CANCERLIT thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE IFIPAT

FILE COVERS 1950 TO PATENT PUBLICATION DATE: 21 Jun 2005 (20050621/PD)
FILE LAST UPDATED: 22 Jun 2005 (20050622/ED)
HIGHEST GRANTED PATENT NUMBER: US6910221
HIGHEST APPLICATION PUBLICATION NUMBER: US2005132458
UNITERM INDEXING IS AVAILABLE IN THE IFIUDB FILE
UNITERM INDEXING LAST UPDATED: 13 Jun 2005 (20050613/UP)
INDEXING CURRENT THROUGH PAT PUB DATE: 4 Jan 2005 (20050104/PD)

INCL, INCLM, INCLS fields added. Please refer to ONLINE News for details.

FILE PHAR

FILE RELOADED May 4, 2003
FILE LAST UPDATED: Jun 20, 2005 (20050620/ED)

A new therapeutic code has been added to PHAR. See HELP THRCODES for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

SUBSCRIBER DISCOUNT AVAILABLE

PJB Publications, Ltd., is offering a discount in the PHAR file to customers who currently subscribe to Pharmaprojects at their particular site. If you are a Pharmaprojects subscriber, please send us your STN Account number and we will apply the discount to those sites who qualify.

Please fax your complete name, address, and STN Account number to our Customer Support Group at: 614-447-3751 or email help@cas.org.

FILE PROMT

FILE COVERS 1978 TO 23 JUN 2005 (20050623/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE PROUSDDR

FILE COVERS 1980 TO 2 May 2005 (20050502/ED)

FILE SYNTHLINE

FILE COVERS 1984 TO 15 May 2005 (20050515/ED)

FILE WPIDS

FILE LAST UPDATED: 21 JUN 2005 <20050621/UP>
MOST RECENT DERWENT UPDATE: 200539 <200539/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
PLEASE CHECK:
<http://thomsonderwent.com/support/dwpieref/reftools/classification/code-rev>
FOR DETAILS. <<<

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JUN 2005 HIGHEST RN 852803-45-3
DICTIONARY FILE UPDATES: 22 JUN 2005 HIGHEST RN 852803-45-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*

* The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	8.85	132.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.73

STN INTERNATIONAL LOGOFF AT 17:14:17 ON 23 JUN 2005